Bay Street News

Gyre Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

Phase 3 clinical trial evaluating F351 for the treatment of CHB-associated liver fibrosis in the PRC remains on track with data anticipated by early 2025

U.S. IND submission to evaluate F351 for the treatment of NASH-associated liver fibrosis expected in late 2024; Phase 2a trial expected to initiate in 2025

Acquired the rights to complementary assets relating to nintedanib through Gyre Pharmaceuticals to improve competitiveness in the PRC

Cash and cash equivalents totaled $29.8 million as of March 31, 2024

SAN DIEGO, May 09, 2024 (GLOBE NEWSWIRE) — Gyre Therapeutics (“Gyre”) (Nasdaq: GYRE), a clinical-stage, self-sustainable biotechnology company developing anti-fibrotic therapeutics for a variety of chronic organ diseases, today announced financial results for the first quarter ended March 31, 2024, and provided a business update.

“Supported by sales of our market-leading IPF drug, ETUARY, Gyre is well-positioned to advance multiple pipeline programs addressing organ fibrosis, including our Phase 3 clinical trial of F351 in CHB-associated liver fibrosis in the PRC that is on track to report data by early 2025,” said Han Ying, Ph.D., Chief Executive Officer of Gyre Therapeutics. “Pending these results, we plan to initiate a Phase 2a trial in the U.S. for F351 in patients with NASH-associated liver fibrosis with the goal of obtaining early proof-of-concept as a basis of expansion into a more comprehensive Phase 2/3 clinical program. We look forward to continuing to grow the company, accelerate our clinical development programs, and strengthen our research and development efforts to bring medicines for fibrotic and inflammatory conditions to patients in need.”

First Quarter 2024 Business Highlights and Upcoming Milestones

ETUARY (Pirfenidone capsules) Sales Update

Clinical Development Updates

F351 (Hydronidone):

F573:

Preclinical Development Updates

Corporate Updates

Financial Results

Cash Position

As of March 31, 2024, Gyre had cash and cash equivalents of $29.8 million, compared to $33.5 million as of December 31, 2023. The $3.7 million change was primarily due to a $2.9 million increase from net cash provided by operating activities, a $7.2 million decrease from net cash used in investing activities and a $0.7 million increase from net cash provided by financing activities. Based on current plans, Gyre anticipates that its cash resources as of March 31, 2024 will enable it to fund operations through at least 12 months following the issuance of the condensed consolidated financial statements.

Financial Results for the Quarter Ended March 31, 2024

Use of Non-GAAP Financial Measures by Gyre Therapeutics, Inc.

Gyre reports financial results in accordance with accounting principles generally accepted in the United States (“GAAP”). This release presents the financial measure “adjusted net income,” which is not calculated in accordance with GAAP. The most directly comparable GAAP measure for this non-GAAP financial measure is “net income.” Adjusted net income presents Gyre’s results of operations after excluding gain from change in fair value of warrants, stock-based compensation, and provision for income taxes. This is meant to supplement, and not substitute, Gyre’s financial information presented in accordance with GAAP. Adjusted net income as defined by Gyre may not be comparable to similar non-GAAP measures presented by other companies. Management believes that presenting adjusted net income provides investors with additional useful information in evaluating the Gyre’s performance and valuation. See the reconciliation of adjusted net income to net income in the section titled “Reconciliation of GAAP to Non-GAAP Financial Measures” below.

About Hydronidone (F351)

F351 is a structural analogue of the approved anti-fibrotic (IPF) drug Pirfenidone and has been shown to inhibit in vitro both p38γ kinase activity and TGF-β1-induced excessive collagen synthesis in hepatic stellate cells (“HSCs”), which are recognized as critical event in the development and progression of fibrosis in the liver. This is further supported by its anti-proliferative effects on the HSCs in the liver. In vitro anti-fibrotic effects of F351 were also confirmed in several established in vivo models of liver fibrosis such as CCI4-induced liver fibrosis mouse model, DMN-induced liver fibrosis rat model, and HSA-induced liver rat model, as well as mouse model of NASH fibrosis (CCI4+Western High Fat Diet).

About Gyre Pharmaceuticals

Gyre Pharmaceuticals is a commercial-stage biopharmaceutical company committed to the research, development, manufacturing and commercialization of innovative drugs for organ fibrosis. Its flagship product, ETUARY (Pirfenidone capsule), was the first approved treatment for IPF in the PRC in 2011 and has maintained a prominent market share (2023 net sales of $112.1 million). In addition, Gyre Pharmaceuticals is evaluating F351 in a Phase 3 clinical trial in CHB-associated liver fibrosis in the PRC, which is expected to readout topline data by early 2025. F351 received Breakthrough Therapy designation by the National Medical Products Administration’s (“NMPA”) Center for Drug Evaluation in March 2021. Gyre Pharmaceuticals is also developing treatments for COPD, PAH and ALF/ACLF. In October 2023, Gyre Therapeutics acquired an indirect majority interest in Gyre Pharmaceuticals (also known as Beijing Continent Pharmaceuticals Co., Ltd.).

About Gyre Therapeutics

Gyre Therapeutics is a biopharmaceutical company headquartered in San Diego, CA, with a primary focus on the development and commercialization of F351 (Hydronidone) for the treatment of NASH-associated fibrosis in the U.S. Gyre’s development strategy for F351 in NASH is based on the company’s experience in NASH rodent model mechanistic studies and CHB-induced liver fibrosis clinical studies. Gyre is also advancing a diverse pipeline in the PRC through its indirect controlling interest in Gyre Pharmaceuticals, including ETUARY therapeutic expansions, F573, F528, and F230.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, which statements are subject to substantial risks and uncertainties and are based on estimates and assumptions. All statements, other than statements of historical facts included in this press release, are forward-looking statements, including statements concerning: the expectations regarding Gyre’s research and development efforts, timing of expected clinical readouts, including timing of topline data from Gyre Pharmaceuticals’ Phase 3 clinical trial evaluating F351 for the treatment of CHB-associated liver fibrosis in the PRC, the U.S. IND submission of F351, initiation of Gyre’s Phase 2a trial and comprehensive Phase 2/3 clinical program in the U.S. for F351, the expectations regarding generic drug nintedanib, interactions with regulators, expectations regarding future product sales, and Gyre’s financial position and cash resources. In some cases, you can identify forward-looking statements by terms such as “may,” “might,” “will,” “objective,” “intend,” “should,” “could,” “can,” “would,” “expect,” “believe,” “design,” “estimate,” “predict,” “potential,” “plan” or the negative of these terms, and similar expressions intended to identify forward-looking statements. These statements reflect our plans, estimates, and expectations, as of the date of this press release. These statements involve known and unknown risks, uncertainties and other factors that could cause our actual results to differ materially from the forward-looking statements expressed or implied in this press release. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation: Gyre’s ability to execute on its clinical development strategies; positive results from a clinical trial may not necessarily be predictive of the results of future or ongoing clinical trials; the timing or likelihood of regulatory filings and approvals; competition from competing products; the impact of general economic, health, industrial or political conditions in the United States or internationally; the sufficiency of Gyre’s capital resources and its ability to raise additional capital. Additional risks and factors are identified under “Risk Factors” in Gyre’s Annual Report on Form 10-K for the year ended December 31, 2023 filed on March 27, 2024 and in other filings with the Securities and Exchange Commission.

Gyre expressly disclaims any obligation to update any forward-looking statements whether as a result of new information, future events or otherwise, except as required by law.

For Investors:
Stephen Jasper
stephen@gilmartinir.com

     
Gyre Therapeutics, Inc.
Condensed Consolidated Statements of Operations
(Unaudited)
(In thousands, except share and per share amounts)
     
  Three Months Ended March 31,  
  2024     2023  
Revenues $ 27,172     $ 24,931  
Operating expenses:          
Cost of revenues   979       1,125  
Selling and marketing   12,542       12,768  
Research and development   2,182       2,635  
General and administrative   3,398       1,739  
Total operating expenses   19,101       18,267  
Income from operations   8,071       6,664  
Other income (expense), net:          
Interest income, net   328       184  
Other income   109       66  
Change in fair value of warrant liability   4,288        
Other expenses   (315 )     (643 )
Income before income taxes   12,481       6,271  
Provision for income taxes   (2,546 )     (2,054 )
Net income   9,935       4,217  
Net income attributable to noncontrolling interest   2,403       1,973  
Net income attributable to common stockholders $ 7,532     $ 2,244  
Net income per share attributable to common stockholders:          
Basic $ 0.09     $ 0.04  
Diluted $ 0.03     $ 0.03  
Weighted average shares used in calculating net income per share attributable to common stockholders:          
Basic   83,265,879       63,588,119  
Diluted   102,594,197       78,921,366  
               
               
           
Gyre Therapeutics, Inc.
Condensed Consolidated Balance Sheets
(Unaudited)
(In thousands, except share and per share amounts)
           
  March 31, 2024     December 31, 2023  
  (Unaudited)        
Assets          
Current assets:          
Cash and cash equivalents $ 29,785     $ 33,509  
Short-term bank deposits   7,567     $  
Accounts and note receivables, net   15,458       15,552  
Other receivables from GNI   1,287       1,287  
Inventories, net   4,939       4,281  
Prepaid assets   1,790       1,547  
Other current assets   1,897       1,045  
Total current assets   62,723       57,221  
Property and equipment, net   23,564       23,288  
Long-term receivable from GCBP   4,780       4,722  
Intangible assets, net   196       205  
Right-of-use assets   359       489  
Land use rights, net   1,480       1,493  
Deferred tax assets   5,000       4,695  
Long-term certificates of deposit   23,106       23,431  
Other assets, noncurrent   802       995  
Total assets $ 122,010     $ 116,539  
Liabilities, convertible preferred stock, and equity          
Current liabilities:          
Accounts payable $ 330     $ 355  
Deferred revenue   35       39  
Due to related parties   1,362       1,369  
CVR excess closing cash payable   422       1,085  
Accrued expenses and other current liabilities   10,767       11,935  
Income tax payable   6,470       5,054  
Operating lease liabilities, current   100       210  
Total current liabilities   19,486       20,047  
Operating lease liabilities, noncurrent   175       199  
Deferred government grants   203       213  
CVR derivative liability, noncurrent   4,780       4,722  
Warrant liability, noncurrent   8,547       12,835  
Other noncurrent liabilities   48       49  
Total liabilities   33,239       38,065  
Convertible Preferred Stock, $0.001 par value, 5,000,000 shares authorized; nil shares and 13,151 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively         64,525  
Stockholders’ equity:          
Common stock, $0.001 par value, 400,000,000 shares authorized; 85,423,246 shares and 76,595,616 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively   85       77  
Additional paid-in capital   133,199       68,179  
Statutory reserve   3,098       3,098  
Accumulated deficit   (78,006 )     (85,538 )
Accumulated other comprehensive loss   (1,736 )     (1,644 )
Total Gyre stockholders’ equity (deficit)   56,640       (15,828 )
Noncontrolling interest   32,131       29,777  
Total equity   88,771       13,949  
Total liabilities, convertible preferred stock, and equity $ 122,010     $ 116,539  
               
               
   
Gyre Therapeutics, Inc.
Reconciliation of GAAP to Non-GAAP Financial Measures
(Unaudited)
(In thousands)
   
  Three Months Ended March 31,
  2024     2023
Net income $ 9,935     $ 4,217
Gain from change in fair value of warrants (1)   (4,288 )    
Stock-based compensation   11      
Provision for income taxes   2,546       2,054
Non-GAAP adjusted net income $ 8,204     $ 6,271

(1) Reflects adjustments for fair value of warrants based on the Black-Scholes option pricing model.


Bay Street News